Background and objectives: In 68 randomized controlled trials (RCTs), blood pressure (BP) lowering was obtained by using drugs of different classes. We have investigated whether BP lowering by any of the major drug classes is effective in reducing the cardiovascular outcomes. Methods: A total of 55 RCTs (195 267 individuals) were suitable for drug-class meta-analyses. Risk ratios and their 95% confidence intervals of seven fatal and nonfatal outcomes were estimated by a random-effects model. Results: Twelve RCTs (48 898 patients) compared a diuretic with no treatment. SBP/DBP differences of about -12/-5 mmHg were accompanied by significant reductions of all outcomes, including mortality. The same results were obtained by limiting analyses to eight RCTs using low-dose diuretics. Separate analyses for thiazides, chlorthalidone and indapamide (all low dose) showed each subclass was associated with significant reduction of some major outcome. Five RCTs (18 724 patients; SBP/DBP difference -10.5/-7 mmHg) showed beta-blockers significantly reduced stroke, heart failure and major cardiovascular events. In RCTs comparing calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) with placebo smaller SBP/DBP differences were achieved, mostly because in the majority of these later RCTs the antihypertensive drug and placebo were added on a background treatment with other antihypertensive agents. Nonetheless, significant reductions of stroke, major cardiovascular events, cardiovascular and all-cause death were obtained with calcium antagonists (10 RCTs, 30 359 patients); stroke, coronary heart disease, heart failure and major cardiovascular events by ACE inhibitors (12 RCTs, 35 707 patients); and stroke, heart failure and major cardiovascular events by ARBs (13 RCTs, 65 256 patients). Conclusion: BP lowering by all classes of antihypertensive drugs is accompanied by significant reductions of stroke and major cardiovascular events. This supports the concept that reduction of these events is because of BP lowering per se rather than specific drug properties. However, evidence of risk reduction of other events and particularly mortality was obtained so far with some drug classes only. As a result of marked differences in the trial design, total cardiovascular risk, SBP/DBP differences and statistical power, comparisons of meta-analyses of different drug-specific placebo-controlled RCTs appear unwarranted.

Thomopoulos, C., Parati, G., Zanchetti, A. (2015). Effects of blood pressure lowering on outcome incidence in hypertension: 4. effects of various classes of antihypertensive drugs - Overview and meta-analyses. JOURNAL OF HYPERTENSION, 33(2), 195-211 [10.1097/HJH.0000000000000447].

Effects of blood pressure lowering on outcome incidence in hypertension: 4. effects of various classes of antihypertensive drugs - Overview and meta-analyses

PARATI, GIANFRANCO
Secondo
;
2015

Abstract

Background and objectives: In 68 randomized controlled trials (RCTs), blood pressure (BP) lowering was obtained by using drugs of different classes. We have investigated whether BP lowering by any of the major drug classes is effective in reducing the cardiovascular outcomes. Methods: A total of 55 RCTs (195 267 individuals) were suitable for drug-class meta-analyses. Risk ratios and their 95% confidence intervals of seven fatal and nonfatal outcomes were estimated by a random-effects model. Results: Twelve RCTs (48 898 patients) compared a diuretic with no treatment. SBP/DBP differences of about -12/-5 mmHg were accompanied by significant reductions of all outcomes, including mortality. The same results were obtained by limiting analyses to eight RCTs using low-dose diuretics. Separate analyses for thiazides, chlorthalidone and indapamide (all low dose) showed each subclass was associated with significant reduction of some major outcome. Five RCTs (18 724 patients; SBP/DBP difference -10.5/-7 mmHg) showed beta-blockers significantly reduced stroke, heart failure and major cardiovascular events. In RCTs comparing calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) with placebo smaller SBP/DBP differences were achieved, mostly because in the majority of these later RCTs the antihypertensive drug and placebo were added on a background treatment with other antihypertensive agents. Nonetheless, significant reductions of stroke, major cardiovascular events, cardiovascular and all-cause death were obtained with calcium antagonists (10 RCTs, 30 359 patients); stroke, coronary heart disease, heart failure and major cardiovascular events by ACE inhibitors (12 RCTs, 35 707 patients); and stroke, heart failure and major cardiovascular events by ARBs (13 RCTs, 65 256 patients). Conclusion: BP lowering by all classes of antihypertensive drugs is accompanied by significant reductions of stroke and major cardiovascular events. This supports the concept that reduction of these events is because of BP lowering per se rather than specific drug properties. However, evidence of risk reduction of other events and particularly mortality was obtained so far with some drug classes only. As a result of marked differences in the trial design, total cardiovascular risk, SBP/DBP differences and statistical power, comparisons of meta-analyses of different drug-specific placebo-controlled RCTs appear unwarranted.
Articolo in rivista - Articolo scientifico
angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; beta-blockers; bloodpressure-lowering treatment; calcium antagonists; diuretics; drug class; hypertension; meta-analysis; randomized controlled trials;
English
2015
33
2
195
211
reserved
Thomopoulos, C., Parati, G., Zanchetti, A. (2015). Effects of blood pressure lowering on outcome incidence in hypertension: 4. effects of various classes of antihypertensive drugs - Overview and meta-analyses. JOURNAL OF HYPERTENSION, 33(2), 195-211 [10.1097/HJH.0000000000000447].
File in questo prodotto:
File Dimensione Formato  
Effects of blood pressure 4 Effects of various classes-Hyperten 2014.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 665.35 kB
Formato Adobe PDF
665.35 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/60282
Citazioni
  • Scopus 179
  • ???jsp.display-item.citation.isi??? 161
Social impact